Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

  • Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021
  • As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program
  • Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics

Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. 

As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic substance – in order to develop clinical-stage compounds for diseases with high unmet medical needs, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is the perfect candidate to participate in psychedelics events. 

In a recent press release (https://ibn.fm/Z8Ify), Tryp announced it would present at one such event: the virtual Psychedelics in Psychiatry and Beyond Conference slated for Thursday, June 17, 2021, and sponsored by H.C. Wainwright & Co., one of America’s oldest and most trusted investment banks focused on equity research and capital market activity. 

As part of Tryp’s presentation to be made available on-demand from 7 a.m. EDT on the day of the conference, Chairman and CEO Greg McKee will offer insight into the company’s business as well as its research-backed pipeline, including the proprietary Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program. 

The PFN program is Tryp’s psychedelics-centered drug development platform targeting certain neuropsychiatric disorders, including fibromyalgia, chronic pain, and eating disorders. The program’s lead drug candidate, TRP-8802, is expected to proceed directly to Phase 2a clinical trials as Tryp intends to leverage existing preclinical and clinical data from the expansive body of research on the active pharmaceutical ingredients in TRP-8802. This approach is expected to accelerate the drug development process toward ultimate approval by the US Food and Drug Administration (“FDA”).

The company intends to further expand research into other indications for psilocybin that, up until this point, have received little attention from pharmaceutical companies. By collaborating with multiple academic institutions and leading principal investigators, Tryp expects to develop new novel treatments, thereby addressing the significant unmet medical needs.

Designed for public and private companies, industry executives, business development executives, venture capitalists, private equity firms, and institutional investors, the conference will feature company presentations, one-on-one investor meetings, and networking opportunities. Attendees should look forward to gaining a deep understanding of psychedelics and the future of this vital class of compounds in psychiatric applications as well as other uses.

Tryp will present alongside other leading pharmaceutical companies currently building a robust R&D pipeline of psychedelic-assisted therapeutics. These include Mindset Pharma Inc. (https://ibn.fm/kUTKb) and Mydecine Innovations Group (https://ibn.fm/178sr), among others. 

To register for the event, attendees can use the following link: https://ibn.fm/5uuv1

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050